Duloxetine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Duloxetine

Examples of brand names: Cymbalta [EU/DE]

ATC code: N06AX21

Main use (for orientation): Depression; neuropathic pain

Documented research summary

Sequential use after discontinuation and series involving several concomitant medicines do not establish an isolated CBD–duloxetine interaction. Direction and magnitude not established.

Uncertainties and limitations

No quantitative human pharmacokinetics for the pair in the documented dataset.

Observed additional benefit with several analgesics proves neither synergy nor safety of the individual pairing.

The country and pharmaceutical formulation of the prescribing information remain relevant; not a complete German market assessment.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Theoretical context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Theoretical plausibility; no verified clinical pair effect

Mechanism / drug context: Duloxetine: CYP1A2/2D6 and hepatic-risk context.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Duloxetine hydrochloride, delayed-release capsules from Golden State Medical Supply, US publication dated 25 August 2026. Sections 1, 7 and all subsections of 12 read. Active SNRI, extensive hepatic oxidation by CYP1A2 and CYP2D6 followed by conjugation; principal metabolites without a substantial contribution to activity. Duloxetine moderately inhibits CYP2D6. Liver function, serotonergic burden, bleeding risk and sedating concomitant substances are relevant. Do not present fluvoxamine/paroxetine effect sizes as cannabinoid effects.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [RLABEL_D0107]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: DULOXETINE DELAYED-RELEASE (DULOXETINE HYDROCHLORIDE) CAPSULE, DELAYED RELEASE PELLETS [GOLDEN STATE MEDICAL SUPPLY, INC.] [RLABEL_D0107]

Source role [RMED39065685]: Scope distinction / context

Statement supported: CBD after duloxetine discontinuation; no evidence of simultaneous exposure.

Source: Impact of Cannabidiol and Exercise on Clinical Outcomes and Gut Microbiota for Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors: A Case Report. [RMED39065685]

Source role [RMED30418116]: Scope distinction / context

Statement supported: Multiple medicines in a small clinical series, not isolated duloxetine pharmacokinetics.

Source: Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. [RMED30418116]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[RLABEL_D0107] DULOXETINE DELAYED-RELEASE (DULOXETINE HYDROCHLORIDE) CAPSULE, DELAYED RELEASE PELLETS [GOLDEN STATE MEDICAL SUPPLY, INC.]

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[RMED39065685] Impact of Cannabidiol and Exercise on Clinical Outcomes and Gut Microbiota for Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors: A Case Report.

Original source / bibliographic reference

Authors: Vigano M, Kubal S, Lu Y, Habib S, Samarani S, Cama G, Viau C, Farzin H, Koudieh N, Xia J, Ahmad A, Vigano A, Costiniuk CT.

Year: 2024

Source type: Original publication; see finding for study type

DOI: 10.3390/ph17070834

PMID: 39065685

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[RMED30418116] Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study.

Original source / bibliographic reference

Authors: Yassin M, Oron A, Robinson D.

Year: 2019

Source type: Original publication; see finding for study type

PMID: 30418116

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility